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Introduction
In recent years considerable progress has been made in understanding the genetic basis of the development of human oral squamous cell carcinoma (HOSCC). It is well established that an accumulation of genetic alterations is the basis for the progression from a normal cell to a cancer cell, referred to as multi-step carcinogenesis [1] . Progression is enabled by the increasingly more aberrant function of genes that positively or negatively regulate aspects of proliferation, apoptosis, genome stability, angiogenesis, invasion and metastasis [2] . Gene function can be altered in different ways: tumor suppressor genes may be inactivated by mutation, deletion or methylation and oncogenes can be activated by mutation or amplification. A description of these alterations and how these are detected has previously been described [3] [4] [5] . Oral cancers are characterized by a multitude of these genetic alterations and ongoing research is focusing on identifying the critical genetic events and the order in which they occur during carcinogenesis. Frequently occurring genomic alterations are supposed to contain the genes that are the most important for the development of a certain type of cancer [6] . Common alterations for oral cancer are inactivation of TP53 (located at 17p13), gain of chromosomal material at 3q26 and 11q13, and losses at 3p21, 13q21 and 14q32 [7, 8] . For most of these regions the putative tumor suppressor genes or oncogenes still need to be identified. In general, loss of chromosomal material (allelic losses) at 3p, 9q and 17p was observed in a relatively high proportion of dysplastic lesions and therefore these alterations were interpreted to be early markers of carcinogenesis. Several studies suggest, however, that early genetic changes do not necessarily correlate with altered morphology.
Although recent improvements in the diagnosis and treatment of malignant tumors have extended the average length of patients' lives, the incidence of multiple primary malignant tumors is increasing [9] . In particular, it has been reported that patients with head and neck cancer often develop multiple primary neoplasms [10] . This phenomenon has been attributed to 'field cancerization', a concept based in the hypothesis that prolonged exposure to certain risk factors, such as tobacco products, leads to the independent transformation of multiple epithelial cells at several distinct anatomic sites [11] .
In addition, it is now becoming clear that the tumor microenvironment, which is largely orchestrated by inflammatory cells, is an indispensable participant in the neoplastic process, fostering proliferation, survival and migration. Recent data have expanded the concept that tumor microenvironments including hypoxia, and inflammation that are the critical components of tumor progression. Many cancers arise from sites of infection, chronic irritation and inflammation. Many tumors also contain hypoxic microenvironments, a condition that is associated with poor prognosis and resistance to treatment [12] . Thus, oral carcinogenesis is a highly complex multifactorial process that takes place when epithelial cells are affected by several genetic alterations. The use of molecular biology techniques to diagnose oral cancerous lesion might be markedly improved the detection of alterations that are invisible under the microscope.
This review presents up-to-date evidence on molecular markers that have shown promising results in evaluating the efficacy of oral cancer treatments, with the potential to markedly increase the patient survival rate.
Field cancerization
In 1953, Slaughter et al. [11] proposed the concept of field cancerization to explain the strong tendency for patients who are exposed repeatedly to carcinogenic factors such as tobacco and alcohol, to develop multiple primary tumors. These factors presumably increase the likelihood of developing multiple independent malignant foci in the mucosal epithelium that is exposed to them.
At present, oral field cancerization is thought to involve 3 different stages. First, mucosal changes presumably occur in the entire epithelial surface of the head and neck region. These are considered to result from exposure to carcinogens capable of causing multiple genetic abnormalities that develop independently of each other throughout the entire anatomic region [13] . After the initial event, 2 types of migration might be involved in the further development of the cancer: for example, there could be migration of tumor cells by dissolution in saliva (micrometastases), or intraepithelial migration of the progeny of the initially transformed cells [13] . However, it is difficult to imagine that progenitor cells with minimal genetic alterations have the capacity to migrate intraepithelially over great distances, or that they could become established elsewhere after displacement by salivary flow. Indeed, it is known that small numbers of early transformed cells that are surrounded by normal cells usually do not succeed in developing into a new lesion. It is reported that an increase in the proliferation rate in parabasal layers of oral mucosal epithelia distant from an HOSCC is an indicator of the risk of developing new tumors [14] . An aspect of head and neck neoplastic development that is still unresolved, however, is the precise mechanism that underlies the pathogenesis of multiple tumors in this region. Modern molecular techniques may elucidate overall understanding of the biology of these tumors, and ways to devise therapeutic strategies to best manage these lesions, and thereby improve prospects for survival [15, 16] . 3 . Genetic alterations 3.1 . Tumor suppressor gene (Tables 1 and 2) Alterations of the p53 tumor suppressor gene are the most frequently documented genetic abnormalities in human cancer, especially, oral squamous cell carcinomas. Therefore, p53 gene and its related factors were selected in this section. Cylindromatosis (CYLD) gene was nominated as a gene that associated with adenoid cystic carcinoma, one of the typical malignant salivary gland tumors.
p53
The p53 gene is a tumor suppressor that encodes a protein with a molecular weight of 53 kDa that can arrest the cell cycle at the late G1 phase in cells with sub-lethal damage in their genome until their complete repair, or induce apoptosis in cases of irreparable injury [17] . Among the genetic changes involved, inactivation of the p53 tumor suppressor gene by point mutation and allele loss is considered to be the most common event underlying malignancies of every organ [18] . These alterations also seem to be related to the multistep processes of oral carcinogenesis [19] [20] [21] [22] [23] . Mutations of the p53 gene are dispersed over several hundred base pairs in the midregion of the gene. They occur predominantly in exons 5-8, which are hence known as hot regions [24, 25] , and these mutations remain stable during metastasis [26] . Mutations of p53 must occur during early stages in the development of head and neck SCCs because they are already present in premalignant lesions [27] . Mutations of p53 gene are not necessarily the critical, sole, nor the consistent culprit in oral SCCs patients, however, between 30% and 50% of SCCs of this region have been reported to harbor p53 gene alterations [24, 25, 28] . By contrast, other markers are less suitable due to their lack of stability, variability, or difficulties with technical requirements for their detection. The genes that occur high frequent alterations more than p53 have not been found so far. Furthermore, it has been described that cancer with the mutated p53 gene is resistant to radio-/chemotherapy and the patient has poor prognosis than cancer patient with the wild-type p53 gene [29] . Therefore, analysis of mutations in this particular gene gives a good indication of clonal expansion of malignancies and important prognostic information. Because the wild-type form of p53 has a half-life of only 6-30 min, the protein cannot be generally detected by immunohistochemistry; however, if the DNA is damaged, p53 protein accumulates and becomes detectable [30] . So, to assess the frequency of p53 mutations in HOSCCs and the correlations between p53 immunohistochemical detections and p53 gene alterations, we examined them by use of the formalin-fixed, paraffin-embedded specimens from 40 patients with oral SCC treated in the Department of Oral and Maxillofacial Surgery, Meikai University Hospital, Saitama, Japan, from 1970 to 2001. Diagnosis of oral lesions was based on histological examination of hematoxylin and eosin-stained slides. Of the 40 SCC patients, there were 34 men and 6 women, whose ages ranged from 48 to 92 years, with a mean age of 66.2 years. A majority of the patients were over 50 years of age. All specimens were obtained from surgical biopsies that no patients had undergone chemotherapy or radiotherapy preoperatively. As the results of immunohistochemistry using MAb p53 antibody, 22 of 40 cases (55%) were positive. Then the alterations in exons 5-8 of the p53 gene were analyzed by PCR-SSCP and direct sequencing. The p53 point mutations were detected in 14 of 40 cases (35%) ( Table 1) . Similarly, a patient with multiple primary carcinomas, including 4 separate cancers of the head and neck region, which we previously reported [31] , had no correlations between p53 immunoreactivity and the detection of p53 gene alterations. These findings support those of previous reports [32] .
On the other hands, cancer development is principally sporadic; however, since the concept of a constitutional predisposition for neoplasia was suggested by Rokitansky and Virchow [33] , the occurrence of non-random clusters of tumors has been recognized. Hereditary cancer syndromes involving inherited gene mutations, such as Li-Fraumeni syndrome, have also been described [33] . Li-Fraumeni syndrome is a rare familial multiple cancer syndrome associated with germline p53 mutations and characterized by a striking aggregation of multiple tumors of early onset. The familial clustering in this syndrome is due to an inherited predisposition rather than environmental factors [34] [35] [36] [37] . Li-Fraumeni syndrome has been shown to involve a wide range of tumors, including oral cancer. The condition predisposes patients to an increased frequency of second primary cancers [33, 38] .
In general, functional inactivation of the p53 gene may be an early event of carcinogenesis, and corresponding alteration of p53 could contribute to oral carcinogenesis. Therefore, evaluation of the p53 gene status should have clinical value. A multidisciplinary treatment approach is also important for maximizing functional ability and survival rates. It is possible that multidisciplinary treatment, combined with molecular analysis of the tumors, could offer molecular mechanism-based strategies for treating oral cancer that are tailored for the individual patient.
p53R2 gene
The p53 is thought to be involved in DNA repair by the transcriptional activation of a ribonucleoside diphosphate reductase (RR) gene, after exposure to genotoxic stresses [39] . RR plays an essential role in converting ribonucleoside diphosphate to 2 0 -deoxyribonucleoside diphosphate. In an RR holoenzyme, large a and small b subunits form an a 2 b 2 heterotetramer that is required for RR activity [40] . In humans, one large subunit (M1) and two small subunits (hRRM2 and p53R2) of RR have been identified [39] . Two RR small subunits, p53R2 and hRRM2, have an 80% similarity in protein sequence, and the expression of hRRM2 is elevated at the onset of the S-phase of the cell cycle [39] . However, only p53R2 expression is induced by wild-type p53 in response to various genotoxic stresses, including g-irradiation, UV-irradiation, or exposure to adriamycin, whereas expression of hRRM2 occurred in a cell cycle-dependent manner and was in fact suppressed in response to DNA damage [39] . It was reported that DNA synthesis in cells arrested in G1 or G2 after DNA damage was mediated through the RR activity of p53R2 and concluded that p53R2 might be directly involved in processes designed to repair the damage [39] . A p53R2 translocates to the nucleus upon DNA damage, and subsequently, supplies an immediate pool of dNTPs necessary for DNA repair. The p53R2 gene is localized on human chromosome 8q23.1 [39] and some investigators have suggested that the genomic instability often seen in cancers lacking wildtype p53 may reflect the dysfunction of RR due to the failure of p53R2 induction [39, 41, 42] . In response to DNA damage, p53R2, rather than hRRM2, was induced to facilitate DNA repair in p53 wild-type cells [39, 41, 43] . However, hRRM2 can complement the p53R2 function in response to UV irradiation if p53 is dysfunctional [44] . A recent report suggested that p53R2 had metastasis-suppressing ability in colon cancer, and down-regulation of p53R2 by siRNA increased the invasion potential of cancer cells [45] .
The p53R2 is the latest RR subunit to be identified, and its association with oral cancer cell invasive potential has not yet been determined. Therefore, to determine whether the p53R2 plays a role for DNA synthesis of HOSCC, we attempted to investigate the correlation of p53R2 expression with oral cancer invasion in vitro and in vivo and found that p53R2 was negatively associated with the invasion of oral SCC [46] ( Table 1) .
In conclusion, these findings suggested that the suppression or damage of p53R2 function has occurred, and as the results, the induction of apoptosis was inhibited at the invasive front in early stage of HOSCC, regardless of p53 mutation.
p33
ING1b gene Inhibitor of growth, ING tumor-suppressor family proteins (ING1-5) have been discovered during the past decade. Especially, biological properties of ING1 suggested that it was a negative growth regulator acting as a class II tumor suppressor [47] , playing a role in oncogenesis, apoptosis, DNA repair, and cell cycle regulation [48, 49] . Three alternatively spliced transcripts of ING1 have been reported that encode p47 ING1a , p33 ING1b , and p24 ING1c [50] [51] [52] . The p33 ING1b protein is the best-characterized and most widely expressed isoform of the ING1 candidate tumor suppressor in human normal tissues [50] . The ING1 proteins were frequently downregulated but less frequently mutated in human malignancies, including neuroblastomas, colon carcinoma, head and neck squamous cell carcinomas, breast, gastric, esophageal, lymphoid, lung, and brain tumors, whereas they were increased in melanoma, papillary thyroid carcinoma, and ductal breast carcinoma, concomitant with loss of nuclear localization [53] [54] [55] . Furthermore, ING1 protein has been reported to bind directly to p53 protein by immunoprecipitation in vitro, modulating the function of p53 as a transcription activator [56] . ING1 gene is mapped on human chromosome, 13q33-34, a region that has been implicated in the progression of various tumors [57, 58] .
The p33
ING1b has a close relationship with p53 and that neither p53 nor p33
ING1b alone can cause cell growth inhibition [56, 59] , which prompted us to investigate their potential role in oral carcinogenesis. In our study, to determine whether the p33
ING1b isoform plays a role in chemosentivity of HOSCC, we investigated the effect of p33
ING1b overexpression on taxol-induced apoptosis and the activation of caspases in HOSCC cells. Previous experimental evidences indicated that the p33
ING1b may cooperate with p53 in taxol-induced apoptosis of the HOSCC. To test this hypothesis, the HOSCC cell lines, contained wild-type p53 and mutant p53, were employed to examine the enhancement of apoptosis by p33
ING1b overexpression and its mechanism. In addition, the correlations between p53, p53R2, p33
ING1b expression and clinicopathological variables in HOSCC tissues were examined immunohistochemically and summarized in Table 1 . It was not correlated between immunoreactivity for p53, p53R2, p33
ING1b and clinicopathological variables though. It was suggested that the difference of these results caused by the interference of the ubiquitin proteasomal degradations.
In summary, our study demonstrated [60] that p33
ING1b enhanced taxol-induced apoptosis through p53-dependent pathway in KB cells with p53 wild type of HOSCC. The overexpression of p33 ING1b promotes a chain reaction ultimately leading to cell death through caspase-dependent apoptosis pathway. The results suggest that p33
ING1b plays a significant role in the crucial tumor-suppressor pathways. As such, p33
ING1b may prove to be an important marker and/or therapeutic target in the prevention and treatment of HOSCC.
Cylindromatosis (CYLD) gene
Molecular studies of familial and sporadic cylindromas, that arise from the eccrine or apocrine cells of the skin [61, 62] , have shown frequent alterations at chromosome 16q12-13, recently found to house the cylindromatosis (CYLD) gene [63] [64] [65] [66] . CYLD, a tumor suppressor gene, has deubiquitinating enzyme activity and inhibits the activation of transcription factor NF-kB [65, [67] [68] [69] , which has key roles in inflammation, immune responses, tumorigenesis and protection against apoptosis [70] [71] [72] . In most cells, NF-kB is kept inactive in the cytoplasm as a heterodimeric complex composed of p50 and p65 (RelA) subunits bound to the inhibitory protein, inhibitor of kB (IkBa) [73] [74] [75] . Insight into the signaling mechanisms that lead to IkBa phosphorylation have identified a high-molecular weight protein complex known collectively as the IkB kinase (IKK) signalosome and including IKKa, IKKb and IKKg also known as NF-kB essential modulator (NEMO) [76, 77] . IKKa and IKKb have been identified as catalytic subunits, whereas IKKg is a regulatory subunit [76, 78] . Generally, after stimulation by various reagents, IkBa is phosphorylated at serine residues 32 and 36 by IKKa and IKKb, together with the scaffold protein NEMO/IKKg [67] [68] [69] 79] . Serine phosphorylation results in polyubiquitination of IkB and its subsequent degradation by the proteasome, allowing NF-kB to translocate to the nucleus and activate its target gene [71, 79, 80] . At this point, CYLD binds to NEMO/ IKKg and appears to regulate its activity through deubiquitination of TRAF2 [68, 69] . Therefore, loss of the deubiquitinating activity of CYLD is correlated with tumorigenesis. It has been reported that expression of CYLD is detectable in brain, testis, skeletal muscle, spleen, liver, heart, lung and leukocytes [65] . We have also demonstrated previously [81] that the human salivary gland tumor cell line HSG, spontaneously expresses CYLD mRNA and protein.
Adenoid cystic carcinoma (ACC) is well known as a typical malignant salivary gland tumor. Facial palsy caused by perineural invasion of ACCs is particularly frequent. ACC was previously referred to as cylindroma because of its remarkable histologic resemblance to dermal cylindroma. We further found that ACC arising from the hard palate was distinctly positive for CYLD and NF-kB-related factors, immunohistochemically [81] . However, it is unclear whether loss of CYLD is associated with development of salivary gland tumors. We attempted to examine the function of CYLD in HSG cells. Furthermore, the expression and distribution of CYLD, NF-kB and NF-kB-related factors were also investigated in 17 cases of ACC, to elucidate whether CYLD is associated with development of salivary gland tumors (Table  2) . No correlations were detected between clinicopathological variables and expression of CYLD or NF-kB-related factors though.
Based on these in vitro and in vivo observations, one can hypothesize that loss of CYLD function leads to NF-kB activation and subsequently anti-apoptosis, and that as a consequence, it might be associated with tumorigenesis, including growth, development and perineural invasion in human salivary gland tumors, such as ACC [82] .
Adhesion molecule
Cell adhesion molecules (CAMs) are found on the surfaces of all cells, where they bind to extracellular matrix molecules or to receptors on other cells. The expression of CAMs is normally tightly regulated, thereby controlling cell proliferation, mobility, differentiation, and survival. Many of these processes are misregulated in malignant tumors, and it has been shown that many of the characteristics of tumor cells are attributable to the aberrant expression or function of CAMs. New CAMS are still being identified, and the families are becoming increasingly complicated. At present, four main groups are described: the integrins, cadherins, selectins, and the immunoglobulin (Ig) superfamily [83] . A separate group includes molecules such as CD44 which do not classify into any of the other specific categories [83] . The role of CD44, which is also known as a marker of stem cells in oral epithelial tumors, is uncertain in keratinocytes. Splice variants of CD44 possibly involved in migration and proliferation [83] .
Here, we would like to introduce 'neural cell adhesion molecule' which belongs in the Ig superfamily that associated with perineural invasion in adenoid cystic carcinoma, one of the typical malignant salivary gland tumors.
Neural cell adhesion molecule (NCAM) (Table 3)
Neural cell adhesion molecule (NCAM) is a family of cell surface glycoproteins and plays an important role in the development of the nervous system, regulating cell migration, axonal outgrowth, branching, and fasciculation [84] . NCAM consists of several isoforms derived from alternative splicing of one gene [85] [86] [87] . The three major isoforms with molecular masses of 120,140 and 180 kDa have similar extracellular parts, but differ in the disposition of their domains, which are cytoplasmic for the two larger polypeptides [88, 89] . Furthermore, NCAM expression is upregulated by transforming growth factor (TGF)-b [90] [91] [92] . Although NCAM was initially described only in neural tissue, it has also been found in human fetal muscle, kidney, colon and lung as well as in elements of the hemopoietic system. Moreover, it has been reported that NCAM is expressed on a variety of human neoplasms and involved in perineural invasions in various neoplasms, such as bile duct cancer, gallbladder cancer, melanoma and adenoid cystic carcinoma of the head and neck [93] [94] [95] [96] [97] [98] . We also demonstrated previously that NCAM is constitutively expressed in human submandibular salivary gland tumor cell line HSG, in vitro [99] . NCAM is considered to mediate adhesion between cells through a Ca 2+ -independent homophilic (NCAM-NCAM) binding mechanism, and between neurons and the extracellular matrix through heterophilic binding (NCAM binding to another ligand or counter-receptor) [84] . It has been shown that exogenously added NCAM can inhibit the proliferation of cultured neonatal astrocytes and astrocytes responding to a penetrating lesion in the adult rat brain in vivo [100, 101] , suggesting that these effects were mediated by homophilic binding to NCAM on the astrocyte membrane.
The ACCs are biologically aggressive and can give rise to metastases many years after excision of the primary tumor. Facial palsy is particularly frequent, causing perineural invasion. However, it is still unclear whether NCAM is associated with development in this type of salivary gland tumor. We therefore attempted to treat HSG cells with MAb NCAM, in vitro [102] . As shown in Fig. 1 , these results imply that the effect of MAb NCAM is specific to NCAM-expressing tumor cells, such as HSG cells; furthermore, blocking the ability of NCAM through MAb NCAM, as well as the homophilic (NCAM-NCAM) binding mechanism, rather than regulating a signaling pathway of cell proliferation, may in fact induce a negative signal such as apoptosis in HSG cells. In addition, homophilic (NCAM-NCAM) binding may activate multiple signaling pathways that differ among cell types [102] . Furthermore, the expression and distribution of NCAM were also investigated in 13 cases of ACC, to elucidate whether NCAM is associated with development of salivary gland tumors ( Table 3) .
As a conclusion of our study, it is suggested that NCAM might be associated not only with a cell-to-cell adhesion mechanism, but also with tumorigenesis, including growth, development and perineural invasion in human salivary gland tumors. Further studies will be required to identify the signal transduction pathway utilized by glandular tumors after treatment with MAb NCAM and to establish a strategy of NCAM-based salivary gland tumor therapy.
Cytokines
Apoptosis, the process of programmed cell death, is known to be not only necessary for the normal development and homeostasis of an organism, and to involve dramatic changes in cellular structure, but also to provide a defense against transformation and viral invasion [103, 104] . The expression of cytokines and their receptors in human neoplasms has attracted a great deal of interest because of their potential significance for tumor immunity. Members of the tumor necrosis factor (TNF) cytokine family regulate the . Furthermore, TNF-related apoptosis-inducing ligand (TRAIL) is a novel member of the TNF cytokine family that was originally characterized by its ability to induce apoptosis [106, 107] . High expression of TRAIL in peripheral blood leukocytes and in lymphoid tissues such as spleen and thymus has led to the assumption that TRAIL might serve a similar role to that of FasL in the control of peripheral immune responses and in maintaining immune privilege [104] . However, despite their expression of these distinct antigens, tumor elimination by the immune system is often inefficient. Tumor cells may also evade immune attack by expressing FasL, TRAIL or other molecules that induce apoptosis in activated T cells [108] . We also observed in the previous study that tumor cells possess a potential to escape immune surveillance by killing host T lymphocytes through several cytokines such as RCAS1 [109] . In the more recent study, Interleukin (IL)-23 was identified as a cancer-associated cytokine [110] . However, the precise role of IL-23 and its function at the cancer invasive front is controversial.
Receptor-binding cancer antigen expressed on SiSo cells (RCAS1) (Tables 4a-4d)
RCAS1 is a type II membrane protein isolated as a human tumor-associated antigen by a mouse monoclonal antibody (22-1-1 antibody) against a human uterine adenocarcinoma cell line, SiSo [111] . RCAS1 acts as a ligand for a putative receptor present on immune cells such as T, B and NK cells and inhibits the growth of receptor-expressing cells, further induces apoptotic cell death [108] . These observations suggest a role of RCAS1 in the immune escape of tumor cells. Although a variety of cancer tissues have been screened [112] [113] [114] [115] [116] [117] [118] [119] [120] and were found to be positive for RCAS1 expression, no data exist as to whether RCAS1 is expressed in the oral cancer. We investigated whether RCAS1 is expressed in HOSCCs or HOSCC cells and whether tumor cells which are expressing RCAS1, induce apoptosis in its receptor-positive cells, PBLs. The apoptotic index (AI) of TILs was also examined in HOSCC tissues. The correlations between RCAS1 expressions and clinicopathological variables in HOSCC and ACC tissues were summarized in Tables 4a and 4b, and Tables 4c and 4d , respectively. As the results, it was demonstrated that RCAS1 was frequently expressed both in HOSCC and ACC, in vitro and in vivo, and its function on KB cells clearly led apoptosis to PBLs in vitro [109] . Our results indicated that RCAS1 expression plays a key role in the immune escape mechanism of oral cancer, thus that RCAS1 expression could be used as a predictor of poor prognosis in patients with oral cancer. Further investigation of the role of RCAS1 will be required to clarify RCAS1-mediated tumor survival and to establish a strategy of RCAS1-based oral cancer therapy.
Tumor necrosis factor-related apoptosisinducing ligand (TRAIL):
Has it gained the license to kill tumor cells? (Table 5) TRAIL, also called APO2 ligand (APO2L), is a novel member of the TNF cytokine family that was originally characterized by its ability to induce apoptosis [106, 107] . It is known that there are at least four closely related receptors which bind TRAIL: death receptor-4 (DR4) and DR5/KILLER, which contain cytoplasmic death domains and signal apoptosis [106, 107] , and decoy receptor-1 (DcR1) [121] [122] [123] that lacks a cytoplasmic tail and inhibits TRAIL function, further DcR2 [124, 125] , which contains a cytoplasmic region with a truncated death domain that does not transduce the death signal [125] . TRAIL interacts with its agonistic receptors DR4 and DR5, inducing apoptosis in a variety of tumor cell lines derived from malignant melanoma, lymphoma, colon carcinoma, lung carcinoma, breast carcinoma, and malignant gliomas [106, 107, 126, 127] . Although DR4 is expressed in many human normal cells and tissues, including spleen and peripheral blood leukocytes, TRAIL induces apoptosis in various tumor cells but not in non-transformed, normal cells [128] . This may be explained by the fact that TRAIL also interacts with the antagonistic decoy receptors DcR1 and DcR2, which are expressed in normal tissues but not in cancer cells [122, 123] . Neither DcR1 nor DcR2 receptors induce apoptosis, but they protect cells from TRAIL-induced apoptosis [122] [123] [124] . To date, the biological relevance of the complex TRAIL receptor system is unknown and conflicting data exists. Nevertheless, because of its preferential cytotoxicity for cancer cells, TRAIL is regarded as a promising anti-cancer weapon that might be highly effective in vivo with few side effects as it has little or no lethal effect on normal tissues.
TRAIL is expressed in most normal human cells and tissues, including peripheral blood leukocytes, spleen, lung and prostate, but not in the brain [107] . However, TRAIL expression in human neoplasms was largely unknown. We investigated whether TRAIL and its receptors are expressed in HOSCCs or HOSCC cell lines and whether these cell lines are sensitive to TRAIL-induced apoptosis.
Our results [129] suggest their potential to escape immune surveillance by killing host T lymphocytes via DR4/TRAIL and DR5/TRAIL interactions, as suggested for Fas [130] [131] [132] . The expression of decoy receptors in tumor cells was, however, a phenomenon that contradicts previous reports [122, 123] . Indeed, several authors have more recently reported that a decoy receptor is also expressed in various tumor types, and our result is consistent with their observations [133] [134] [135] . This fact suggests that tumor cells may evade TRAIL-induced apoptosis by expressing a decoy receptor.
Generally, the most proximal step to suppress a death receptor pathway is inhibition of ligand binding. This could be achieved by lack of or mutations in death receptors [136, 137] , or the presence of decoy receptors [123] [124] [125] [126] . However, it has recently been mentioned by some investigators that there is no correlation between TRAIL receptor expression and susceptibility to TRAIL-induced apoptosis in various tumor types [133] [134] [135] . Moreover, the existence of anti-apoptotic proteins, such as bcl-2, bcl-xL and/or fas-like IL-1 converting enzyme (FLICE)-like inhibitory protein [138, 139] , also appears to be important due to their resistance to death receptor mediated apoptosis. Collectively, our results also suggested possibilities that there is no correlation between TRAIL receptor expression and susceptibility to TRAIL-induced apoptosis in HOSCC cell lines, and that TRAIL-resistant cells may express cytoprotective proteins which block TRAIL-induced apoptosis, or that the apoptotic effect of TRAIL is governed by other mechanisms.
It has also been reported that the combination of TRAIL and an anti-cancer drug acted co-operatively to induce apoptosis in various tumor cells which were resistant to TRAIL or chemotherapy [133, 140, 141] . This TRAIL-based combination with chemotherapeutic agents might be a useful approach for therapeutic strategies for TRAIL-resistant cells.
Further investigation of TRAIL-mediated apoptosis, including the interaction of TRAIL and its receptors in oral cancer cells under various conditions, will be required to establish a strategy of TRAIL-based oral cancer therapy that does not cause liver toxicity.
Interleukin (IL)-12 and IL-23 (Table 5)
The causal relationship between chronic inflammation, innate immunity and cancer is now widely accepted, and the similarities in the regulatory mechanisms have been suggested for more than a century [142, 143] . Many cancers arise at the site of chronic inflammation and inflammatory mediators are often produced in tumors [143, 144] . The frequent use of anti-inflammatory drugs reduces the incidence of a variety of human tumors [145] . Although blockading some of these mediators has been shown to be efficacious in experimental settings, it is still unclear whether the inflammatory reaction at the tumor site promotes tumor growth or simply implies the failed attempt of the immune system to eliminate the rising malignancy.
IL-23, a heterodimeric cytokine with many similarities to IL-12, has recently been identified as a factor linking tumorassociated inflammation and a lack of tumor immune surveillance [146] . IL-23 comprises a p19 subunit that associates with the IL-12p40 subunit [110] , whereas IL-12 is a combination of IL-12p35 and the same IL-12p40 subunit [147] . Although p19 is expressed in various tissues and cell types, it lacks biological activity and only becomes biologically active when complexed with p40, which is normally secreted by activated macrophages and dendritic cells (DCs) [110] . IL-23 uses many of the same signal-transduction components as IL-12, including the IL-12 receptor (R) b1 subunit (IL-12Rb1), Janus kinase (Jak)2, Tyk2, signal transducer and activator of transcription (Stat)1, Stat3, Stat4, and Stat5 [110, 148] . IL-23R, composed of the IL-12Rb1 and the IL-23R subunit, is also expressed in DCs, macrophages, and T cells [148] . Consistent with the structural and biological similarities of IL-12 and IL-23, the IL-23R complex shares a subunit with that of IL-12 (IL-12Rb1); however, it does not use or detectably bind to IL-12Rb2 [110] . The ability of cells to respond to either IL-12 or IL-23 is determined by expression of IL-12Rb2 or IL-23R, respectively [148] . Additionally, both cytokines promote the T helper cell type 1 (Th1) costimulatory function of antigenpresenting cells [149] . However, IL-23 does differ from IL-12 in the T cell subsets that it targets. IL-12 acts on naive CD4 + T cells, whereas IL-23 preferentially acts on memory CD4 + T cells [149] . It has been reported that IL-12 has potent antitumor activity in a variety of murine tumor models, causing regression of established tumors [150] [151] [152] and inhibiting the formation of experimental metastases [150, 151] and spontaneous metastases [153, 154] . On the other hand, it has recently been reported that genetic deletion or antibodymediated elimination of IL-23 in mice leads to increased infiltration of cytotoxic T cells into the transformed tissue, T4N2cM0  IVA  +  27  85  F  Tongue  Moderately  T2N1M0  III  +  28  54  M  Tongue  Moderately  T1N0M0  I  -29  54  M  Tongue  Moderately  T4N2bM0  IVA  +  30  75  M  Mandibular gingiva  Moderately  T1N0M0  I  +  31  66  F  Mandibular gingiva  Moderately  T1N0M0  I  -32  65  M  Mandibular gingiva  Moderately  T2N0M0  II  -33  88  M  Mandibular gingiva  Moderately  T2N0M0  II  +  34  79  M  Mandibular gingiva  Moderately  T2N0M0  II  +  35  54  M  Buccal mucosa  Moderately  T2N0M0  II  +  36  64  M  Buccal mucosa  Poorly  T2N0M0  II  +  37  62  M  Tongue  Poorly  T2N1M0  III  +  38  60  M  Tongue  Poorly  T2N1M0  III  -39  60  M  Tongue  Poorly  T1N0M0  I  -40  68  M  Maxillary gingiva  Poorly  T3N0M0  III  ++ RCAS1 positive 32/40 cases = 80%. rendering a protective effect against chemically induced carcinogenesis [146] . So far, it has been reported that expression of IL-23 and its receptors is detectable in activated macrophages, DCs, and keratinocytes in healthy skin [155] . From our data [156, 157] , two separate lines of evidence allowed us to conclude that IL-23 is a potent and specific promoter of NF-kB activation in HSC-3 cells: (i) IL-23 promoted nuclear transactivation of NF-kB, and (ii) IL-23 increased NF-kB dependent transcriptional activity. Furthermore, our in vivo studies also suggested that IL-23 might promote NF-kB activity, alternatively IL-23 function might be activated by NF-kB in SCC tissues [157] (Table 5) . Finally, we noted that IL-23 was secreted not only by DCs and macrophages, as shown in previous studies [147] , but also by autologous cancer cells. Consequently, we consider the existence of an autocrine mechanism, in which tumor growth is promoted by IL-23 produced by autologous cancer cells. From these combined data, we believe that IL-23 plays a significant role in the growth and proliferation of oral cancer. Thus, IL-23 could be used as a predictor of poor prognosis in patients with oral cancer, and its antibody might be able to use as an inhibitor of oral cancer progression. Identification of the signaling pathways underlying these events might provide the key to elucidating the mechanism of development of oral cancer. Further investigations into the role of IL-23 will be required to fully understand IL-23-mediated tumor proliferation and to establish an IL-23-based oral cancer therapeutic strategy.
Vascular endothelial growth factor (VEGF) (Table 5)
Oral cancer is an important cause of worldwide morbidity and mortality, with substantial economic, physiological, and psychosocial impacts due to its treatment modality and a great risk for recurrences and second primary OSCC development. Therefore, it is very important to understand the underlying cell biology of such tumors. It is now well-accepted fact that angiogenesis is essential for the growth and metastasis of solid tumors, including head and neck squamous cell carcinoma. The main factor responsible for angiogenesis is VEGF and its receptors [158] . It has been demonstrated that VEGFRs are also present on tumor cells themselves and other cells from the tumor microenvironment, in addition to tumoral endothelial cells (ECs) [157] . Therefore between these cells take place numerous and different interactions mediated via paracrine/ autocrine pathways that promote angiogenesis, uncontrolled tumor proliferation and metastasation. In consequence, estimation of VEGF expression and its receptors became a reliable prognostic tool in OSCCS, predicting the poor disease-free survival, poor overall survival, and metastatic disease. Understanding the distribution and role of VEGF and its receptors in the progression of OSCC will be essential to the development and design of new therapeutic strategies.
Transcriptional factor (Table 5)
The ancient stress response is the innate immune response, regulated by several transcription factors, among which NFkappaB plays a central role. The hypoxic response is also ancient stress response triggered by low ambient oxygen (O 2 ) and controlled by hypoxia inducible transcription factor-1, whose a subunit is rapidly degraded under normoxia but stabilized when O 2 -dependent prolylhydroxylases (PHDs) that target its O 2 -dependent degradation domain are inhibited. Thus, the amount of HIF-1alpha, which controls genes involved in energy metabolism and angiogenesis, is regulated post-translationally. So, NF-kappaB and hypoxia-inducible factor-1 were selected as the typical transcriptional factors in this section.
Nuclear factor (NF)-kappaB
Nuclear factor-kB (NF-kB) has key roles in inflammation, immune response, tumorigenesis and protection against apoptosis [70] [71] [72] . A detailed discussion of NF-kB can be found in Section 3.1.4.
Hypoxia inducible factor (HIF)-1alpha
Protection against hypoxia in solid tumors is an important step in tumor development and progression. One system in hypoxia protection of tumor cells is represented by the hypoxia-inducible factor 1 (HIF-1) system which plays a crucial role in biologic processes under hypoxic conditions, especially in angiogenesis and carcinogenesis [159, 160] . HIF-1 is a heterodimer, composed of HIF-1a (120 kDa) and HIF-1b (91, 93, 94 kDa) [161] . HIF-1a subunit, is a transcription factor in response to cellular hypoxia, plays an important role in tumor growth and metastasis by regulating energy metabolism and inducing angiogenesis [162] . However, under normoxic conditions, HIF-1a is maintained at low levels due to continuous degradation via the ubiquitin-dependent proteosome pathway, and this pathway is inhibited by hypoxia and by p53 or von Hippel-Lindau tumor-suppressor gene defects, leading to stabilization of the HIF-1a protein [163] [164] [165] [166] . Therefore, hypoxia can lead to a rapid increase in HIF-1a protein levels [163, [166] [167] [168] . Furthermore, HIF-1a up-regulates a number of important factors for tumor expansion, including VEGF, a key factor in tumor angiogenesis [169] [170] [171] . In several cancers, overexpression of HIF-1a protein has been found to be associated with tumor aggressiveness and with an unfavorable prognosis [159, 172, 173] . Hypoxia has also been reported to induce wild-type p53 via a different pathway than DNA-damaging agents [174] . The hypoxic/ anoxic induction of p53 selects for tumor cells that lack functional p53, and hence evidence diminished apoptotic potential [175] . Elevated levels of HIF-1a are noted in various malignant tumors [159] , but it is unclear whether this is so in oral carcinoma. Therefore, we have examined the implications of HIF-1a expression in HOSCC, in vitro and in vivo. NanoCulture plate system was used to duplicate hypoxic condition within tumor mass of living organisms by the threedimensional cell culture. As the results, we found that HIF-1a regulates the expression of VEGF, and that HIF-1a may be regulated by p53 in SCC of the oral cavity [176] (Table 5) . 7 . As the other anti-cancer drugs: Has it potential of a novel lethal weapon against oral cancer?
Although there are numerous anti-cancer drugs, here, we would daringly like to propose the anti-cancer effect of cimetidine, which is an H2R blocker. Because cimetidine is just a stomach medicine, and it is free of side effects such as that the other anti-cancer drugs have. Furthermore, H2R blockers are comprised of cimetidine, famotidine, and ranitidine, however, it is reported that only cimetidine has a precise effect as the anti-cancer drug.
In addition, although malignant glandular tumors are known to be generally resistant to radiation therapy and chemotherapy, the efficacy of cimetidine is observed occasionally in the clinical application for glandular tumor. Therefore, if cimetidine has an effect of anti-cancer drug for oral cancer, it will be ideal drug in this lesion.
Cimetidine strikes back
Cimetidine, the oldest histamine type-2 receptor (H2R) antagonist to be used clinically, is commonly prescribed to treat gastro-esophageal reflux disease as well as gastric and duodenal ulcers [177] . Although it is like a half-remembered drug, it has recently been reported that cimetidine improves the survival of patients with malignant tumors [178, 179] , including gastric [180] and colorectal carcinomas [181] . Cimetidine has been shown to inhibit growth of gastrointestinal cancers via several mechanisms including enhancement of immune activity and inhibition of cancer T2N0M0  II  -----+  33  88  M  Mandibular gingiva Moderately  T2N0M0  II  ---+  +  +  34  79  M  Mandibular gingiva Moderately  T2N0M0  II  +  +  -++  +  +  35  54  M  Buccal mucosa  Moderately  T2N0M0  II  --+  ++  +  -36  64  M  Buccal mucosa  Poorly  T2N0M0  II  4+  ---+  +  37  62  M  Tongue  Poorly  T2N1M0  III  +  ---+  ++  38  60  M  Tongue  Poorly  T2N1M0  III  ---AE  +  ++  39  60  M  Tongue  Poorly  T1N0M0  I  +  --+  +  +  40  68  M  M. gingiva  Poorly  T3N0M0  III  --+  AE  +  - cell proliferation [179] . Therefore cimetidine may act by enhancing the host immune response against tumor cells [182, 183] or by blocking the cell growth-promoting activity of histamine [183] [184] [185] [186] [187] [188] . Kobayashi et al. [187] reported that cimetidine inhibits colon adenocarcinoma cell adhesion to vascular endothelial cells and prevents metastasis by blocking E-selectin expression. We also demonstrated recently that cimetidine inhibited neural cell adhesion molecule (NCAM) expression and induced apoptosis in salivary gland tumor cells [188] . However, the exact mechanisms by which cimetidine suppresses the development of salivary gland tumors remain to be elucidated. ACC is a well known and typical malignant salivary gland tumor. Facial paralysis due to perineural/neural invasion occurs so frequently that it is generally accepted as a hallmark of ACCs [98] [99] [100] , and inhibition of perineural/ neural invasion could be a strategy for arresting the development of ACC. Then, we have examined the effect of cimetidine on cancer cell adhesion to neural cells in vitro, one of the critical steps of cancer invasion and metastasis. We have also used an in vivo carcinogenesis model to confirm the effect of cimetidine. We demonstrated previously [99] that NCAM is spontaneously expressed in HSG cells and that HSG cell proliferation may be controlled via a homophilic (NCAM-NCAM) binding mechanism. We have also shown that NCAM may be involved in perineural/neural invasion by malignant salivary gland tumors [102] . Furthermore, it has been reported that NCAM expression is regulated by NF-kB and that NF-kB activity is induced by homophilic NCAM binding [189, 190] . In conclusion, our experiments clearly demonstrated that cimetidine effectively downregulates the induction of NCAM by inhibiting the transactivation of NF-kB, which subsequently blocks HSG adhesion to neural cells, and ultimately induces apoptosis in HSG cells and prevents the growth of HSG tumor masses in nude mice in which the salivary gland tumor cell line HSG was injected subcutaneously [191] . These findings may explain clinical observations by several authors [178, 179] that cimetidine improves the survival of patients with malignant tumors. Although malignant glandular tumors are known to be generally resistant to radiation therapy and chemotherapy, the clinical application of cimetidine as an anti-cancer drug might form an integral part of future therapeutic strategies against NCAM-expressing tumors such as adenoid cystic carcinoma. Further studies will be required to identify the signal transduction pathways by which treatment with cimetidine suppresses the growth of glandular tumors and to establish a strategy for cimetidine-based therapy of salivary gland tumors.
Conclusion
Despite major advances in the molecular medicine of oral cancer, there remain numerous gaps in our knowledge of the molecular markers involved in oral carcinogenesis. HOSCCs appear to have a multifocal character, with only half of them developing on the same site as a previous leukoplakia. Complex molecular mechanisms are implicated and the identification of a single marker to predict outcomes in all oral premalignant lesions remains a difficult challenge. Among reported markers are for inactivation of tumor suppressor genes, notably p53, p53R2, p33
ING1b and CYLD. Their study may contribute to the search for reliable molecular markers of the development of oral cancer. Other molecular medicine approaches are emerging, including assessment of the promoter regions of certain genes (e.g. NCAM, RCAS1 and IL-23) or tumor-stroma interactions, which could provide new and promising data. However, it is clear that further study is essential to be used as effective diagnostic and prognostic markers to improve the management of oral cancer patients.
Furthermore, despite advances in detection and medical therapy of oral cancer, mortality of this disease remains high because current therapies are limited by the emergence of therapy-resistant cancer cells, termed oral cancer stem cells (CSCs). CSCs have recently attracted a great deal of interest. The characteristics of CSCs include an ability to proliferate (self-replication capacity) and to differentiate into several cell types with different functions (multidifferentiation capacity), as well as a tumorigenic capacity. However, little is known about the oral CSCs function. It has been described that head and neck cancer indeed follows the CSC hypothesis, since implantation of few cells consistently gives rise to tumors that can be serially passaged in vivo [192] . Therefore, further researches will be required to elucidate the functional interactions between oral CSCs and surrounding stromal cells and to establish a strategy for CSCs-targeted therapy of oral cancer in the near future.
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